Advertisement

Topics

Ensuring Innovation and Competition for Biologics Leads to More Timely Products for Patients

19:07 EDT 13 Jun 2019 | FDA

A robust market for safe, effective biosimilar products is crucial – more products on the market increases competition which can lead to more access and reduced health care costs for patients and our nation’s health care system.

Original Article: Ensuring Innovation and Competition for Biologics Leads to More Timely Products for Patients

NEXT ARTICLE

More From BioPortfolio on "Ensuring Innovation and Competition for Biologics Leads to More Timely Products for Patients"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...